The development of therapeutics that directly target mutant K-Ras has been hampered by a plethora of unfavorable factors, including an incomplete understanding of signaling transduction, feedback loops, redundancy and tumor heterogeneity, and difficulty in developing small-molecule inhibitors against Ras oncoproteins [44]. This evidence concerns the gene KRAS and neoplasm.